Digostics joins Innovate UK Scaleup Programme in recognition of growth and global potential
Digostics joins Innovate UK Scaleup Programme in recognition of growth and global potential
NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in Southampton Become the First Patients Globally to Access Gestational Diabetes Testing at Home.
NHS Hospital Trust Pilot of New Testing Technology Sees Pregnant Women in Southampton Become the First Patients Globally to Access Gestational Diabetes Testing at Home.
Oxford, United Kingdom 07/07/2025 – Digostics, today announced its selection for the highly competitive Innovate UK Scaleup Programme, recognising the company’s exceptional growth potential and breakthrough innovation in diabetes detection.
Delivered by Innovate UK, the Scaleup Programme supports a select group of high-potential companies with innovations capable of transforming markets. The selection follows a rigorous three-stage assessment process evaluating commercial traction, innovation strength, and global scalability.
.png?width=2000&height=1333&name=Picture2%20(3).png "Picture2 (3)")
GTT@home, Digostics’ flagship innovation, revolutionises diabetes screening by bringing the oral glucose tolerance test directly to patients' homes through an innovative digital-first platform. Already adopted by the NHS and transforming the screening of pregnant women for gestational diabetes, the technology eliminates traditional barriers to early detection of diabetes and has generated significant interest from clinicians worldwide.
“This recognition from Innovate UK validates our mission to transform diabetes diagnostics on a global scale”, said James Jackson, CEO of Digostics. “The timing could not be better for Digostics as we are on the cusp of some exciting milestones in our business”.
“As the programme is based on providing us with tailored support to progress our milestones more rapidly over the next 12 to 18 months, we are really looking forward to engaging with the Scaleup Directors assigned to us”.
About Digostics
Far too many people across the world are living with undiagnosed diabetes.
UK-based Digostics' mission is to enable healthcare providers to identify everyone with diabetes, and those at risk of developing diabetes, by eliminating the common barriers that inhibit accurate and timely testing using the gold standard oral glucose tolerance test (OGTT).
Digostics is proud to offer GTT@home - the world’s first home OGTT offering and the most accessible and scalable way for clinical teams to realise their diabetes testing objectives.
To learn more, visit www.digostics.com
About Innovate UK
Innovate UK Business Growth is part of Innovate UK, the UK’s national innovation agency. Part of UK Research and Innovation, it drives productivity and growth, supporting businesses to develop. Innovate UK connects innovators with the funding, expertise and networks they need to accelerate their growth.
“We are very pleased to be partnering with the NIHR Oxford Biomedical Research Centre on this study," said James Jackson, CEO and Founder of Digostics. "We believe that there is huge potential for the widespread use of at-home OGTT testing to diagnose T1D. Not only is it more attractive for young children to be able to be tested at home, but the results from our GTT@home test are not affected by the time-dependent sample degradation that can lead to false negative OGTT results with in-clinic testing."
Dr Rachel Besser, who leads the T1Early programme at the University of Oxford and is overseeing this work, said “A more practical and reliable alternative to the in-clinic OGTT would be a welcome advance and could improve the experience and therefore the uptake of children who have an OGTT as part of their care.”
"We hope this revolutionary new at-home test is going to dramatically change the way we deliver gestational diabetes testing during antenatal care."
Dr Matthew Coleman
Click the button below for more GTT@home product-specific information exploring:
• the GTT@home test kit's contents
• the novel GTT@home test device
• at-home versus in-clinic test comparisons
• patient and healthcare professional support
Click the button below for more GTT@home product-specific information exploring:
• the GTT@home test kit's contents
• the novel GTT@home test device
• at-home versus in-clinic test comparisons
• patient and healthcare professional support
[1] The World Health Organization (WHO) and American Diabetes Association (ADA) recommend that, if OGTT blood samples aren’t tested immediately they should be cooled in an ice slurry and centrifuged within 30 minutes to minimize glucose degradation
[2] Diabetes Medicine. Barriers to completing oral glucose tolerance testing in women at risk of gestational diabetes. E H Lachmann, R A Fox, R A Dennison, J A Usher-Smith, C L Meek, C E Aiken https://pubmed.ncbi.nlm.nih.gov/32144795/
[3] Mother To Baby | Fact Sheets [Internet]. Brentwood (TN): Organization of Teratology Information Specialists (OTIS); 1994-. Gestational Diabetes. 2023 Apr. Available from: https://www.ncbi.nlm.nih.gov/books/NBK582729/?utm_source=chatgpt.com
[4] Pregnancy and Gestational Diabetes: Causes, Risks, Management
[5] Lachmann EH, Fox RA, Dennison RA, Usher-Smith JA, Meek CL, Aiken CE. Barriers to completing oral glucose tolerance testing in women at risk of gestational diabetes. Diabet Med. 2020 Sep;37(9):1482-1489. doi: 10.1111/dme.14292. Epub 2020 Mar 18. PMID: 32144795; PMCID: PMC8641378.
[6] Gnanasambanthan S, Jabak S, Mohan R, Dayoub N, Maduanusi C, Kohli S, Haas-Heger T, Lynch C, Hameed A. The impact of socioeconomic deprivation on the prevalence of gestational diabetes: An observational study. Obstet Med. 2024 Dec;17(4):201-207. doi: 10.1177/1753495X231213920. Epub 2023 Nov 14. PMID: 39640950; PMCID: PMC11615992.
About University Hospital NHS Foundation Trust
University Hospital Southampton NHS Foundation Trust provides services to some 1.9 million people living in Southampton and south Hampshire, plus specialist services such as neurosciences, cardiac services and children's intensive care to more than 3.7 million people in central southern England and the Channel Islands.
UHS is one of the largest acute teaching trusts in England with a staff of 13,000 and a turnover of more than £1bn in 2020/21.
We are one of only two major trauma centres in the South of England for both adults and children.
UHS is consistently one of the UK’s highest recruiting trusts of patients to clinical trials.
Could GTT@home be of assistance to your patients?
Please get in touch by completing the form below or calling us on +44 (0)330 113 9145.
References
¹ International Diabetes Federation - Diabetes Atlas 10th Edition 2021
² NHS Gestational Diabetes Overview
³ International Diabetes Federation - Care and Prevention - Gestational Diabetes
† Pubmed - Future risk of diabetes in mother and child after gestational diabetes mellitus 2009
Images of Matthew Coleman and of University Hospital Southampton's premises are kindly provided by University Hospital Southampton NHS Foundation Trust.